WO2003090771A3 - Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3) - Google Patents

Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3) Download PDF

Info

Publication number
WO2003090771A3
WO2003090771A3 PCT/EP2003/003835 EP0303835W WO03090771A3 WO 2003090771 A3 WO2003090771 A3 WO 2003090771A3 EP 0303835 W EP0303835 W EP 0303835W WO 03090771 A3 WO03090771 A3 WO 03090771A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
therapeutics
diagnostics
diseases associated
trace amine
Prior art date
Application number
PCT/EP2003/003835
Other languages
French (fr)
Other versions
WO2003090771A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to AU2003222812A priority Critical patent/AU2003222812A1/en
Publication of WO2003090771A2 publication Critical patent/WO2003090771A2/en
Publication of WO2003090771A3 publication Critical patent/WO2003090771A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human TA3 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer diseases, respiratory diseases, genito-urinary diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer diseases, respiratory diseases, genito-urinary diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of TA3 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/003835 2002-04-25 2003-04-14 Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3) WO2003090771A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003222812A AU2003222812A1 (en) 2002-04-25 2003-04-14 Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02009223.5 2002-04-25
EP02009223 2002-04-25

Publications (2)

Publication Number Publication Date
WO2003090771A2 WO2003090771A2 (en) 2003-11-06
WO2003090771A3 true WO2003090771A3 (en) 2004-04-08

Family

ID=29265895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003835 WO2003090771A2 (en) 2002-04-25 2003-04-14 Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3)

Country Status (2)

Country Link
AU (1) AU2003222812A1 (en)
WO (1) WO2003090771A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036473A2 (en) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Human g protein-coupled receptors
WO2002081517A2 (en) * 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036473A2 (en) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Human g protein-coupled receptors
WO2002081517A2 (en) * 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby

Also Published As

Publication number Publication date
AU2003222812A1 (en) 2003-11-10
AU2003222812A8 (en) 2003-11-10
WO2003090771A2 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
WO2003082314A3 (en) Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
WO2003081258A3 (en) Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
WO2003074069A3 (en) Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2003090771A3 (en) Diagnostics and therapeutics for diseases associated with trace amine receptor 3(ta3)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2003065044A3 (en) Diagnostics and therapeutics for diseases associated with gpr72
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004042390A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
WO2003083135A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
WO2003080098A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens formyl peptide receptor-like 2
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2003100434A3 (en) Diagnostic and therapeutic use of the arginine vasopressin receptor 2 (avpr2)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
WO2004057328A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)
WO2004071394A3 (en) Diagnostics and therapeutics for diseases associated with hm74
WO2003076945A3 (en) Diagnostic for diseases associated with g-protein coupled receptor 105 (gpr105)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP